Azenosertib (ZN-c3) is another potent WEE1 inhibitor that has proven to be safe in phase I trials in platinum-resistant ovarian cancer and advanced uterine serous carcinoma patients and is currently being studied in BRAF-mutated CRC, in combination with encorafenib and cetuximab (NCT05743036). The gene discussed is BRAF; the disease is colorectal carcinoma.